News

At 1 and 3 years follow-up, sodium oxybate-treated patients showed significant increases in periodic leg movements index and significantly higher apnea-hypopnea index.

The lead of the Myasthenia Gravis Foundation of America Global Myasthenia Gravis Patient Registry spoke on 2 additional attributes of the patient registry. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Analysis on the EARLYSTIM trial assessing deep brain stimulation of the subthalamic nucleus in early Parkinson disease showed maintained speech intelligibility and nonspeech oral movements.

As a recap from ISC 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates and expert insights.

Neurology News Network for the week ending February 18, 2023. [WATCH TIME: 4 minutes]

Teva’s VMAT2 inhibitor was previously approved in a twice-daily formulation. The once-daily extended-release treatment, marketed as Austedo XR, is expected to be available later in 2023 in doses of 6 mg, 12 mg, and 24 mg.

Frequent medication change, adverse events, and low medication adherence appears more frequently in patients with narcolepsy who use complementary and alternative medicine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 17, 2023.

Physicians were nearly 3 times more likely to prescribe treatments for symptoms of suspected dementia with a positive DISCERN result.

The assistant professor of neurology at the Yale School of Medicine spoke about the strength in the patient-clinician relationship in ensuring quality care for myasthenia gravis. [WATCH TIME: 4 minutes]

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

In honor of Duchenne Muscular Dystrophy Awareness Week, held February 13, 2023, to February 19, 2023, get caught up on some of the latest news in Duchenne muscular dystrophy as the NeurologyLive® team shares some of our data updates.

Findings indicated that the robust wake-promoting efficacy of solriamfetol demonstrated in clinical trials resulted in improved real-world functional performance in participants with narcolepsy.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic detailed the current issues with access and affordability to critical biomarkers in the screening and monitoring of patients in Alzheimer disease trials. [WATCH TIME: 3 minutes]

AUPN Leading Edge Episode 5 features Clifton L. Gooch, MD, and Carlayne E. Jackson, MD, FAAN, who discuss the “lessons learned” on the path toward leadership. [LISTEN TIME: 1 hour, 3 minutes]

Although the magnitude of the association for smoking, atrial fibrillation and left ventricular hypertrophy did not decrease, their importance for stroke risk likely increases with age.

The maternal fetal medicine specialist at Hartford HealthCare Medical Group talked about the challenges of prescribing migraine treatment during pregnancy. [WATCH TIME: 4 minutes]

Data showed improvement in excessive daytime sleepiness and cataplexy frequency for children with narcolepsy on pitolisant.

The medical director of the Cooper Neurological Institute spoke at the 2023 International Stroke Conference about notable research themes from the meeting. [WATCH TIME: 10 minutes]

The newly updated label warns patients on aducanumab about the potential risks of brain bleeding, which can be significant and life-threatening.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

The medical director of the Hartford healthcare Headache Center in Connecticut discussed the significance of findings from a study assessing migraine during pregnancy. [WATCH TIME: 4 minutes]

The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided insight on new considerations for interpreting data from cognitive and functional measures in trials assessing agents for Alzheimer disease.

A meta-analysis displayed a small magnitude of pooled effect estimates for the studied skip-amenable mutation classes in Duchenne muscular dystrophy at 1 year follow up.

Investigators concluded that the therapeutic effectiveness of antiparkinsonian medications is short and limited for intolerable abdominal pain.

The director of Cleveland Clinic’s Cerebrovascular Center discussed the decisions mobile stroke units face and why opting for direct transfer to angiography is meant for certain scenarios. [WATCH TIME: 3 minutes]

Episode 30 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Julie Silver, MD, of Harvard Medical School. [WATCH TIME: 8 minutes]